FDA accepts Immunomedics' BLA for sacituzumab govitecan for mTNBC; shares up 2% premarket

|By:, SA News Editor

The FDA accepts for review Immunomedics' (NASDAQ:IMMU) Biologics License Application (BLA) seeking approval to use antibody-drug conjugate sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior lines of therapy. The agency's action date is January 18, 2019.

Shares are up 2% premarket on light volume.

Subscribe for full text news in your inbox